Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
PeaceHealth Oregon/Lane County Behavioral Health Services
mi
from
Eugene, OR
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
PeaceHealth Oregon/Lane County Behavioral Health Services
mi
from
Eugene, OR
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Lehigh Valley Hospital Mental Health Clinic
mi
from
Allentown, PA
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Lehigh Valley Hospital Mental Health Clinic
mi
from
Allentown, PA
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
South Shore Mental Health Center
mi
from
Charlestown, RI
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
South Shore Mental Health Center
mi
from
Charlestown, RI
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
The Providence Center
mi
from
Providence, RI
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
The Providence Center
mi
from
Providence, RI
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Howard Center
mi
from
Burlington, VT
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Howard Center
mi
from
Burlington, VT
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Burrell Behavioral Health
mi
from
Springfield, MO
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Burrell Behavioral Health
mi
from
Springfield, MO
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Henderson Mental Health Center
mi
from
Fort Lauderdale, FL
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Henderson Mental Health Center
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated:  9/7/2017
Community Alternatives
mi
from
Saint Louis, MO
An Integrated Program for the Treatment of First Episode of Psychosis
Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program
Status: Enrolling
Updated: 9/7/2017
Community Alternatives
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia
A Phase 1 Multiple Ascending Oral Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia
Status: Enrolling
Updated:  9/12/2017
Site US10001
mi
from
Glendale, CA
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia
A Phase 1 Multiple Ascending Oral Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia
Status: Enrolling
Updated: 9/12/2017
Site US10001
mi
from
Glendale, CA
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
K & S Professional Research Services
mi
from
Little Rock, AR
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
K & S Professional Research Services
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Comprehensive Clinical Development Inc.
mi
from
Cerritos, CA
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Comprehensive Clinical Development Inc.
mi
from
Cerritos, CA
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Pacific Institute for Medical Research Inc
mi
from
Los Angeles, CA
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Pacific Institute for Medical Research Inc
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
SRSD, Inc. dba Synergy San Diego
mi
from
National City, CA
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
SRSD, Inc. dba Synergy San Diego
mi
from
National City, CA
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
NRC Research Institute
mi
from
Orange, CA
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
NRC Research Institute
mi
from
Orange, CA
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Artemis Institute for Clinical Research
mi
from
San Diego, CA
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Collaborative Neuroscience Network, INC
mi
from
Torrance, CA
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Collaborative Neuroscience Network, INC
mi
from
Torrance, CA
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Comprehensive Clinical Development
mi
from
Washington, D.C.,
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Comprehensive Clinical Development
mi
from
Washington, D.C.,
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Innovative Clinical Research, Inc
mi
from
Lauderhill, FL
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Innovative Clinical Research, Inc
mi
from
Lauderhill, FL
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Florida Clinical Research Center LLC
mi
from
Maitland, FL
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Behavioral Clinical Research, Inc.
mi
from
North Miami, FL
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Behavioral Clinical Research, Inc.
mi
from
North Miami, FL
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Atlanta Center
mi
from
Atlanta, GA
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Atlanta Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Northwestern University
mi
from
Chicago, IL
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Uptown Research Institute, Llc
mi
from
Chicago, IL
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Uptown Research Institute, Llc
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Mid-America Clinical Research, LLC
mi
from
Saint Louis, MO
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Mid-America Clinical Research, LLC
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
St. Louis Clinical Trials, LLC
mi
from
Saint Louis, MO
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
St. Louis Clinical Trials, LLC
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Neurobehavioral Research, Inc.
mi
from
Cedarhurst, NY
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Neurobehavioral Research, Inc.
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Finger Lakes Research
mi
from
Rochester, NY
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Finger Lakes Research
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Univ of Rochester Medical Center
mi
from
Rochester, NY
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Richmond Behavioral Associates
mi
from
Staten Island, NY
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Richmond Behavioral Associates
mi
from
Staten Island, NY
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Community Clinical Research
mi
from
Austin, TX
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Community Clinical Research
mi
from
Austin, TX
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
InSite Clinical Research LLC
mi
from
DeSoto, TX
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
InSite Clinical Research LLC
mi
from
DeSoto, TX
Click here to add this to my saved trials
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated:  9/19/2017
Dr. Alexander McIntyre Inc.
mi
from
Penticton,
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
Status: Enrolling
Updated: 9/19/2017
Dr. Alexander McIntyre Inc.
mi
from
Penticton,
Click here to add this to my saved trials
A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youths With Psychosis
Meals, Mindfulness & Moving Forward: A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youth Suffering From Psychosis
Status: Enrolling
Updated:  9/19/2017
Oregon Health and Science University
mi
from
Portland, OR
A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youths With Psychosis
Meals, Mindfulness & Moving Forward: A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youth Suffering From Psychosis
Status: Enrolling
Updated: 9/19/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia
Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia
Status: Enrolling
Updated:  9/21/2017
Maryland Psychiatric Research Center
mi
from
Catonsville, MD
Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia
Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia
Status: Enrolling
Updated: 9/21/2017
Maryland Psychiatric Research Center
mi
from
Catonsville, MD
Click here to add this to my saved trials
Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-way Pagers
2-Way Pagers to Improve Schizophrenia Medication Adherence
Status: Enrolling
Updated:  9/22/2017
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-way Pagers
2-Way Pagers to Improve Schizophrenia Medication Adherence
Status: Enrolling
Updated: 9/22/2017
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
Click here to add this to my saved trials
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
Status: Enrolling
Updated:  10/3/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
Status: Enrolling
Updated: 10/3/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
Status: Enrolling
Updated:  10/3/2017
Pilgrim Psychiatric Center
mi
from
Brentwood, NY
Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
Status: Enrolling
Updated: 10/3/2017
Pilgrim Psychiatric Center
mi
from
Brentwood, NY
Click here to add this to my saved trials
Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
Status: Enrolling
Updated:  10/3/2017
Mount Sinai Hosp
mi
from
New York, NY
Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
Status: Enrolling
Updated: 10/3/2017
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Internal Monitoring of Eye Movement in Schizophrenia
Internal Monitoring of Eye Movement in Schizophrenia
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Internal Monitoring of Eye Movement in Schizophrenia
Internal Monitoring of Eye Movement in Schizophrenia
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Screening for Childhood-Onset Psychotic Disorders
Screening, Evaluation, Diagnosis, Treatment Optimization and Follow-up for Childhood Onset Psychotic Disorders
Status: Enrolling
Updated:  10/6/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Screening for Childhood-Onset Psychotic Disorders
Screening, Evaluation, Diagnosis, Treatment Optimization and Follow-up for Childhood Onset Psychotic Disorders
Status: Enrolling
Updated: 10/6/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Garden Grove, CA
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
National City, CA
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
National City, CA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Sacramento, CA
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
San Diego, CA
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Torrance, CA
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Chicago, IL
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials